After the Fed released minutes of its last meeting, the bond market signaled it fears the Fed will not be aggressive enough with its rate cutting.Market Insiderread more
The Fed minutes also note that "a couple" members wanted a 50 basis point cut, based primarily on the weak inflation readings.The Fedread more
Japanese manufacturing activity shrank for a fourth straight month in August as export orders fell at a sharper pace.Asia Marketsread more
Analysts generally doubt how effective the People Bank of China's latest interest rate announcement will be in significantly helping businesses grow.China Economyread more
The Washington governor had centered his campaign around climate change, calling it "the most urgent challenge of our time."Politicsread more
The inversion is seen by many veteran traders as an important recession omen, though the timing on the eventual downturn is less predictable.Bondsread more
Here's what Nordstrom reported for its fiscal second-quarter earnings.Retailread more
The sexy image that once boosted Victoria's Secret has been haunting L Brands more recently, as women are steering clear of the brand's hot pink, lacy and bejeweled lingerie.Retailread more
Ford is one of four automakers that reached a voluntary agreement with California on fuel efficiency rules, defying Trump and his administration's effort to strip the state of...Autosread more
See which stocks are posting big moves after the bell.Market Insiderread more
"I'd love to say that the optimistic universe is most likely to prevail, but the talking heads talk endlessly about how a recession is inevitable," CNBC's Jim Cramer says.Mad Money with Jim Cramerread more
AmerisourceBergen, one of the largest U.S. drug wholesalers, will pay the federal and state governments $625 million to resolve civil claims over its illegal distribution of adulterated and misbranded drugs, including syringes for cancer patients, New York's attorney general said on Monday.
The settlement followed a related September 2017 guilty plea by the company's AmerisourceBergen Specialty Group unit, which included $260 million of criminal fines and forfeitures.
Authorities accused the unit's Medical Initiatives pharmacy subsidiary in Alabama of causing numerous false claims to be submitted to Medicaid for unapproved new drugs, and for defective or compromised new drugs.
They also faulted the unit for illegally shipping pre-filled syringes that contained drugs for patients in chemotherapy, and which were prepared in an unsterile environment. These drugs included Aloxi, Anzemet, Kytril, Neupogen and Procrit.
"We have zero tolerance for big corporations that skirt federal and state laws to boost their profits at the expense of vulnerable individuals," New York Attorney General Barbara Underwood said in a statement.
AmerisourceBergen has said it set aside $625 million for the settlement in its fiscal year ended Sept. 30, 2017.